ArticleCancer medicine2024

Referred molecular testing as a barrier to optimal treatment decision making in metastatic non-small cell lung cancer: Experience at a tertiary academic institution in Canada.

Grace K Grafham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.